BRCA2 and ovarian cancer: With BRCA status providing prognostic information (Candido-dos-Reis et al. 2015) and helping to predict sensitivity to cytotoxic agents (Tan et al. 2008), ovarian cancer management now sees patients “being selected in clinical practice for biomarker-directed therapy, based on presence of a BRCA1 or BRCA2 mutation” (George et al. 2017).